|
May 16, 2022
|
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
|
|
|
May 12, 2022
|
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
|
|
|
Apr 28, 2022
|
Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares
|
|
|
Apr 25, 2022
|
Nkarta Announces Pricing of Upsized Public Offering of Common Stock
|
|
|
Apr 25, 2022
|
Nkarta Announces Proposed Public Offering of Common Stock
|
|
|
Apr 25, 2022
|
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
|
|
|
Apr 22, 2022
|
Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates
|
|
|
Apr 08, 2022
|
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022
|
|
|
Apr 08, 2022
|
Nkarta to Participate at Upcoming Investor Conference
|
|
|
Mar 29, 2022
|
Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors
|
|
